Tumor infiltration by exhausted CD8+ T cells is a strong predictor of response to therapy (6, 7) and pre-clinical animal studies have indicated that certain exhausted cell subsets are required for therapeutic efficacy (5, 8–10). The gene discussed is CD8A; the disease is neoplasm.